Supplementary Figure 11 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure 11. TAA burden in responders and non-responders of nivolumab treatment in HNSC patients stratified based on Ecotyper CD8 S3 scores. Figure shows the patients from a neoadjuvant trial of advanced-stage HNSC patients treated with the anti-PD-1 antibody nivolumab (Obradovic dataset). P-values are based on one-tailed Welch’s T test.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7164989017
